1-(4-氟苯基)环丙烷甲酸 | 773100-29-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 1-(4-氟苯基)环丙烷甲酸
• 中文别名: (4-氟苯基)环丙基羧酸
• 英文名称: 1-(4-fluorophenyl)cyclopropane-1-carboxylic acid
• 英文别名: 1-(4-fluorophenyl)cyclopropanecarboxylic acid
• CAS: 773100-29-1
• 化学式: C₁₀H₉FO₂
• mdl: MFCD06208777
• 分子量: 180.179
• InChiKey: NGVPHOXWSFIYNV-UHFFFAOYSA-N

物化性质

• 沸点：
  303.5±35.0 °C(Predicted)
• 密度：
  1.361±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  37.3
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 危险等级：
  IRRITANT
• 危险品标志：
  Xi
• 海关编码：
  2916399090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H315,H319,H335

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 1-(4-Fluorophenyl)cyclopropanecarboxylic acid
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 1-(4-Fluorophenyl)cyclopropanecarboxylic acid
CAS number: 773100-29-1

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C10H9FO2
Molecular weight: 180.2

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, hydrogen fluoride.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  1-(4-氟苯基)环丙烷甲酸 在 lithium aluminium tetrahydride 、 草酰氯 、 三乙胺 、 N,N-二甲基甲酰胺 、 三氟乙酸 作用下， 以 四氢呋喃 、 二氯甲烷 为溶剂， 反应 5.67h， 生成 [1-(4-氟苯基)环丙基]甲基胺
  参考文献：
  名称：

  Positive Allosteric Modulators of MGLUR2

  摘要：

  该披露通常涉及到公式I的化合物，包括它们的盐，以及使用这些化合物的组合物和方法。这些化合物调节mGluR2受体，可能有助于治疗中枢神经系统的各种疾病。

  公开号：

  US20130245042A1
• 作为产物：
  描述：

  1-(4-氟苯基)环丙腈 在 lithium hydroxide 作用下， 以 水 为溶剂， 生成 1-(4-氟苯基)环丙烷甲酸
  参考文献：
  名称：

  铑催化环丙基CH键的对映选择性硅烷化

  摘要：

  氢硅烷基醚是通过环丙基甲醇与二乙基硅烷的脱氢硅烷化原位生成的，在源自铑前体和双膦的铑催化剂存在下，以高收率和高对映体过量进行环丙基CH键的不对称分子内硅烷化（ S )-DTBM-SEGPHOS。所得的对映体富集的氧杂硅氧烷是 Tamao-Fleming 氧化形成环丙醇的合适底物，同时保留了 C−H 甲硅烷基化的ee值。初步的机制数据表明，C−H 裂解可能是转换限制和对映选择性决定步骤。

  DOI：

  10.1002/anie.201603153

文献信息

• Methods and Compositions for Selectin Inhibition
  申请人：Kaila Neelu

  公开号：US20080255192A1

  公开（公告）日：2008-10-16

  The present teachings relate to novel compounds of formula I: wherein the constituent variables are as defined herein. Compounds of the present teachings can act as antagonists of the mammalian adhesion proteins known as selecting. Methods for treating or preventing selectin-mediated disorders are provided, which include administration of these compounds in a therapeutically effective amount.

  本教学涉及到式I的新化合物： 其中组成变量如本文所定义。本教学的化合物可以作为被称为选择素的哺乳动物粘附蛋白的拮抗剂。提供了治疗或预防选择素介导的疾病的方法，包括以治疗有效剂量给予这些化合物。
• Piperazine derivatives useful as CCR5 antagonists
  申请人：Schering Corporation

  公开号：US06391865B1

  公开（公告）日：2002-05-21

  The use of CCR5 antagonists of the formula or a pharmaceutically acceptable salt thereof, wherein R is optionally substituted phenyl, pyridyl, thiophenyl or naphthyl; R1 is hydrogen or alkyl; R2 is substituted phenyl, substituted heteroaryl, naphthyl, fluorenyl, diphenylmethyl or optionally substituted phenyl- or heteroaryl-alkyl; R3 is hydrogen, alkyl, alkoxyalkyl, cycloalkyl, cycloalkylalkyl, or optionally substituted phenyl, phenylalkyl, naphthyl, naphthylalkyl, heteroaryl or heteroarylalkyl; R4, R5 and R7 are hydrogen or alkyl; R6 is hydrogen, alkyl or alkenyl; for the treatment of HIV, solid organ transplant rejection, graft v. host disease, arthritis, rheumatoid arthritis, inflammatory bowel disease, atopic dermatitis, psoriasis, asthma, allergies or multiple sclerosis is disclosed, as well as novel compounds, pharmaceutical compositions comprising them, and the combination of CCR5 antagonists of the invention in combination with antiviral agents useful in the treatment of HIV or agents useful in the treatment of inflammatory diseases.

  公开了使用CCR5拮抗剂的公式，其中 R是可选择的取代苯基，吡啶基，噻吩基或萘基; R1是氢或烷基; R2是取代苯基，取代杂环基，萘基，芴基，二苯甲基或可选择的取代苯基或杂环基烷基; R3是氢，烷基，烷氧基烷基，环烷基，环烷基烷基，或可选择的取代苯基，苯基烷基，萘基，萘基烷基，杂环基或杂环基烷基; R4，R5和R7是氢或烷基; R6是氢，烷基或烯基; 用于治疗HIV，固体器官移植排斥，移植物宿主病，关节炎，类风湿关节炎，炎症性肠病，特应性皮炎，牛皮癣，哮喘，过敏或多发性硬化症的方法，以及包含它们的新化合物，包含它们的药物组合物，以及CCR5拮抗剂与抗HIV治疗中有用的抗病毒剂或与治疗炎症性疾病中有用的药物的组合。
• Systematic Investigation of Halogen Bonding in Protein–Ligand Interactions
  作者：Leo A. Hardegger、Bernd Kuhn、Beat Spinnler、Lilli Anselm、Robert Ecabert、Martine Stihle、Bernard Gsell、Ralf Thoma、Joachim Diez、Jörg Benz、Jean‐Marc Plancher、Guido Hartmann、David W. Banner、Wolfgang Haap、François Diederich

  DOI：10.1002/anie.201006781

  日期：2011.1.3

  Halogen bonding triggers activity: Increasing binding affinity was observed for a series of covalent human Cathepsin L inhibitors by exchanging an aryl ring H atom with Cl, Br, and I, which undergo halogen bonding with the CO group of Gly61 in the S3 pocket of the enzyme. Fluorine, in contrast, strongly avoids halogen bonding (see scheme). The strong distance and angle dependence of halogen bonding

  卤素键触发活性：通过将芳环H原子与Cl，Br和I交换，可以观察到一系列共价的人组织蛋白酶L抑制剂的结合亲和力增加，Cl，Br和I与S3口袋中的Gly61的CO基团进行卤素键合酶。相反，氟强烈避免卤素键（参见方案）。卤素键的强距离和角度依赖性已被证实适用于生物系统。
• NOVEL PROLINE DERIVATIVES
  申请人：Sánchez Rubén Alvarez

  公开号：US20100267722A1

  公开（公告）日：2010-10-21

  The invention relates to a compound of formula (I) wherein A, R 1 -R 6 are as defined in the description and in the claims. The compound of formula (I) can be used as a medicament.

  这项发明涉及一种化合物，其化学式为（I），其中A，R1-R6如描述和权利要求中所定义。化合物的化学式（I）可用作药物。
• MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR PROTEIN
  申请人：AbbVie S.à.r.l.

  公开号：US20170305891A1

  公开（公告）日：2017-10-26

  The present invention provides for compounds of formula (I) wherein R 1 , m, Z, G 1 , R 2 , and R 3 have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions mediated and modulated by CFTR, including cystic fibrosis, Sjögren's syndrome, pancreatic insufficiency, chronic obstructive lung disease, and chronic obstructive airway disease. Also provided are pharmaceutical compositions comprised of one or more compounds of formula (I).

  本发明提供了以下式（I）的化合物，其中R1、m、Z、G1、R2和R3具有规范中定义的任何值，以及其药学上可接受的盐，这些化合物可用作治疗由CFTR介导和调节的疾病和症状的药物，包括囊性纤维化、Sjögren综合征、胰腺功能不全、慢性阻塞性肺病和慢性阻塞性气道疾病的药物。还提供了由一个或多个式（I）化合物组成的药物组合物。